Boron-containing small molecules as anti-protozoal agents

Patent metadata

Field	Value
Publication number	US-9493489-B2
Application number	US-200913062450-A
Country	US
Kind code	B2
Filing date	Oct 15, 2009
Priority date	Oct 15, 2008
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

First claim

What is claimed is:

1. A compound, or a salt thereof, having a structure according to the following formula:

wherein
R* is H or negative charge; and
X is selected from the group consisting of substituted phenyl, unsubstituted heteroaryl, substituted heteroaryl, and unsubstituted cycloalkyl;
wherein said substituted phenyl is phenyl, substituted with at least one member selected from the group consisting of halogen, cyano, nitro, OR, SR, NRR, unsubstituted alkyl, substituted alkyl, unsubstituted heteroalkyl, substituted heteroalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl,
wherein each R is independently selected from the group consisting of unsubstituted alkyl, substituted alkyl, unsubstituted heteroalkyl, substituted heteroalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl.

2. The compound of claim 1 , or a salt thereof, wherein X is phenyl, substituted with at least one member selected from the group consisting of: halogen, cyano, nitro, OR, SR, NRR, unsubstituted alkyl, substituted alkyl, unsubstituted heteroalkyl, substituted heteroalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl,
wherein each R is independently selected from the group consisting of unsubstituted alkyl, substituted alkyl, unsubstituted heteroalkyl, substituted heteroalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heterocycloalkyl, substituted heterocycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl.

3. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:

wherein
Y 1 is a halogen;
Y is halo-substituted C 1 -C 6 alkyl.

4. The compound of claim 3 , or a salt thereof, wherein said Y 1 is a halogen, and said halogen is fluoro.

5. The compound of claim 3 , or a salt thereof, wherein said Y is halo-substituted C 1 -C 6 alkyl, and said halo-substituted C 1 -C 6 alkyl is trifluoromethyl.

6. The compound of claim 3 , or a salt thereof, having a structure according to the following formula:

7. The compound of claim 3 , or a salt thereof, having a structure according to the following formula:

8. The compound of claim 3 , or a salt thereof, having a structure according to the following formula:

9. A combination comprising the compound of claim 1 , or a salt thereof, together with at least one other therapeutically active agent.

10. A pharmaceutical formulation comprising:
a) the compound of claim 1 , or a pharmaceutically acceptable salt thereof; and
b) a pharmaceutically acceptable excipient.

11. The pharmaceutical formulation of claim 10 , wherein the pharmaceutical formulation is a unit dosage form.

12. The compound of claim 1 , wherein the salt of said compound is a pharmaceutically acceptable salt.

13. A method of killing and/or inhibiting the growth of a protozoa, comprising: contacting the protozoa with an effective amount of the compound of claim 1 , or a salt thereof, thereby killing and/or preventing the growth of the protozoa, wherein the protozoa is of a genus selected from the group consisting of Trypanosoma, Leishmania , and Plasmodium.

14. The method of claim 13 , wherein the compound is according to claim 1 , or a salt thereof.

15. The method of claim 13 , wherein the protozoa is of the genus Trypanosoma.

16. The method of claim 13 , wherein the protozoa is Trypanosoma brucei.

17. The method of claim 16 , wherein the Trypanosoma brucei is selected from the group consisting of Trypanosoma brucei brucei, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense.

18. A method of treating a disease in an animal, comprising: administering to the animal a therapeutically effective amount of the compound of claim 1 , or a salt thereof, thereby treating the disease, wherein the disease is associated with a protozoa of a genus selected from the group consisting of Trypanosoma, Leishmania , and Plasmodium.

19. The method of claim 18 , wherein the compound is according to claim 1 .

20. The method of claim 18 , wherein the disease is sleeping sickness.

21. The method of claim 18 , wherein the animal is a human.

22. The compound of claim 2 , or a salt thereof, wherein X is phenyl, substituted with at least one member which is halosubstituted alkyl.

23. The compound of claim 2 , or a salt thereof, wherein X is phenyl, substituted with at least one member which is trifluoromethyl.

24. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:

wherein Y is halo-substituted C 1 -C 6 alkyl.

25. The compound of claim 24 , or a salt thereof, wherein Y is C 1 -C 6 alkyl, substituted with one, two, three, or four halogens.

26. The compound of claim 24 , or a salt thereof, wherein Y is C 1 -C 6 alkyl, substituted with one, two, three, or four fluorines.

27. The compound of claim 24 , or a salt thereof, wherein Y is C 1 -C 6 alkyl, substituted with one, two, three, or four chlorines.

28. The compound of claim 24 , or a salt thereof, wherein Y is trifluoromethyl.

29. The compound of claim 24 , or a salt thereof, which is N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-2-(trifluoromethyl)benzamide.

30. The compound of claim 24 , or a salt thereof, which is N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-3-(trifluoromethyl)benzamide.

31. The compound of claim 24 , or a salt thereof, which is N-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-4-(trifluoromethyl)benzamide.

32. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:

wherein Y 5 is halosubstituted C 1 -C 6 alkoxy.

33. The compound of claim 32 , or a salt thereof, wherein Y 5 is substituted with one or two or three halogens.

34. The compound of claim 32 , or a salt thereof, wherein said Y 5 is halosubstituted C 1 -C 6 alkoxy, and said halosubstituted C 1 -C 6 alkoxy is fluoro-substituted C 1 -C 6 alkoxy.

35. The compound of claim 32 , or a salt thereof, wherein said Y 5 is halosubstituted C 1 -C 6 alkoxy, and said hal

Assignees

• Jacobs Robert
• Orr Matthew
• Wring Stephen
• Chen Daitao
• Zhou Huchen
• Ding Dazhong
• Feng Yiqing
• Yi Long
• Hernandez Vincent S
• Zhang Yong-Kang
• Plattner Jacob J
• Anacor Pharmaceuticals Inc

Inventors

• Jacobs Robert
• Orr Matthew
• Wring Stephen
• Chen Daitao
• Zhou Huchen
• Ding Dazhong
• Feng Yiqing
• Yi Long
• Hernandez Vincent S
• Zhang Yong-Kang
• Plattner Jacob J

Classifications

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• C07F5/025 Primary

  Boronic and borinic acid compounds · CPC title

• A61K31/69

  Boron compounds · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title